May 15th 2024
“The association of lower testosterone concentrations with higher all-cause mortality was present irrespective of luteinizing hormone concentrations, indicating that low testosterone was the main factor," says Bu B. Yeap, MBBS, FRACP, PhD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Clinical hypogonadism and the urologist’s role: Primum non nocere
July 9th 2014I consider urology to be a very unique field, one that I am lucky to be part of. Recently, though, I have begun to wonder whether the medical community (not necessarily the urology community) has been too quick to embrace the widespread use of testosterone replacement therapy.
Robotic RP associated with improved margin status
July 7th 2014Robot-assisted radical prostatectomy may be associated with improved surgical margin status compared to open radical prostatectomy for men with intermediate-risk and high-risk prostate cancer, according to a study presented at the AUA annual meeting in Orlando, FL.
Prostate EBRT linked with risk of two other cancers
June 30th 2014Men with prostate cancer who are treated with external beam radiation therapy are at an increased risk for cancer of the bladder and rectum 10 years or more after their prostate cancer diagnosis, according to an analysis using data from the Surveillance, Epidemiology, and End Results program.
Clinicians say active surveillance is effective but rarely recommend it
June 30th 2014The majority of urologists and radiation oncologists feel active surveillance is an effective and underused modality for managing low-risk prostate cancer; however, few of these specialists would recommend this strategy to patients, according to recent survey results.
CCP score strong predictor of localized PCa outcomes
June 16th 2014Results of a validation study confirm that cell cycle progression score provided by a commercially available genomic test (Prolaris) is a strong and independent outcome predictor in men with conservatively managed, clinically localized prostate cancer.
Androgen deprivation therapy overuse still problematic among some urologists
June 9th 2014Inappropriate use of a gonadotropin-releasing hormone agonist for androgen deprivation therapy of localized prostate cancer fell dramatically following implementation of reimbursement cuts mandated by the Medicare Modernization Act of 2003, but overuse remains problematic, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.
FDA OKs low T nasal gel, male incontinence device
June 2nd 2014The FDA has approved a nasal gel for men with hypogonadism and has granted clearance to a treatment for urinary incontinence in men. Separately, two drug makers are approaching the agency about regulatory approval for an over-the-counter version of a phosphodiesterase-type-5 inhibitor.
Early chemo-ADT combination may be new PCa standard
June 2nd 2014A new study showing a survival benefit of more than 1 year with a chemotherapy-hormonal therapy combination given prior to castration resistance is being hailed by the study’s first author as a “new standard” of treatment for certain men with metastatic, hormone-sensitive prostate cancer.
Prostate ‘hoax’ book contains no conspiracy theories
May 30th 2014Dr. Henry Rosevear’s blog post about my recently published book, “The Great Prostate Hoax: How big medicine hijacked the PSA test and caused a public health disaster,” does a disservice to the readership of the Urology Times by mischaracterizing the book’s central message.
Alpha-blockers top choice for first-line LUTS treatment
May 29th 2014Most urologists turn to alpha-blockers as first-line treatment for BPH-related lower urinary tract symptoms, while transurethral resection of the prostate remains the most commonly used surgical modality, according to a recent survey.
AUA look-back: TRT safety, PCa tests spark news, debate
May 29th 2014The recently concluded AUA annual meeting in Orlando may not go down as one of the most memorable annual meetings in recent years. Nevertheless, it was noteworthy for some interesting news and lively debate on hot-button topics: the safety of certain urologic products, namely, testosterone and transvaginal mesh; new tests for prostate cancer; infection prevention and treatment; and use of an advanced prostate cancer agent in the pre-chemotherapy setting.
TRT shows benefit, no harm in post-RP patients
May 19th 2014Testosterone replacement therapy may be considered for treatment of hypogonadism in carefully selected men who have undergone radical prostatectomy for low- to intermediate-risk prostate cancer, according to researchers from New York University Medical Center, New York.